iRhythm Technologies, Inc. - Common Stock (IRTC)

SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQIRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the fourth quarter and full year 2024 after the close of trading on Thursday, February 20, 2025. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

SAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQIRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 43rd Annual J.P. Morgan Healthcare Conference.

SAN FRANCISCO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQIRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference.

SAN FRANCISCO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQIRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Citi 2024 Global Healthcare Conference.

Five new studies span three focus areas for LTCM devices: digital engagement and patient satisfaction, arrhythmia patterns during sleep and activity, and the potential health care resource and economic impact of early arrhythmia detection in patients with type 2 diabetes and COPD

SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQIRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Wolfe Research 2024 Healthcare Conference.

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against iRhythm Technologies, Inc. (NASDAQIRTC) on behalf of long-term stockholders following a class action complaint that was filed against iRhythm on February 6, 2024 with a Class Period from January 11, 2022, to May 30, 2023. Our investigation concerns whether the board of directors of iRhythm have breached their fiduciary duties to the company.

Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients

SAN FRANCISCO, Oct. 30, 2024 (GLOBE NEWSWIRE) --  iRhythm Technologies, Inc. (NASDAQIRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2024.

SAN FRANCISCO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQIRTC), a leading digital health company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that the results of the Extended Ambulatory ECG Monitoring Enhances Identification of Higher-Risk Ventricular Tachyarrhythmias in Patients with Hypertrophic Cardiomyopathy (EXAMINE-HCM) study have been published in Heart Rhythm Journal. The findings were also presented at the Heart Rhythm Society’s annual meeting in 2023, and most recently, at the International HCM Summit 8 in Boston, MA (October 25-28, 2024).

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into iRhythm Technologies, Inc. (NasdaqGS: IRTC).

Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients

SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQIRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2024 after the close of trading on Wednesday, October 30, 2024. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into iRhythm Technologies, Inc. (NasdaqGS: IRTC).

SAN FRANCISCO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQIRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that it has received regulatory approval from the Japanese Pharmaceutical and Medical Device Agency (PMDA) for the Zio® fourteen-day, long-term continuous ECG monitoring system. With regulatory approval in hand, iRhythm intends to work towards a reimbursement decision for the Zio ECG monitoring system with the Japanese Ministry of Health, Labour, and Welfare (MHLW).

SAN FRANCISCO, Sept. 09, 2024 (GLOBE NEWSWIRE) --  iRhythm Technologies, Inc. (NASDAQIRTC) today announced initial research findings on post-market, real-world performance of Zio® monitor, its next-generation Zio® long-term continuous monitoring (LTCM) patch ECG device, presented at the Heart Rhythm Society’s HRX 2024 meeting.

iRhythm granted exclusive license to BioIntelliSense’s patented pulse oximetry, accelerometry and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring (ACM) market

SAN FRANCISCO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQIRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the presentation and publication of the GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals) randomized clinical trial at the European Society of Cardiology (ESC) Congress 2024. The trial was sponsored by Bristol-Myers Squibb-Pfizer Alliance and iRhythm provided the Zio XT patch ECG long-term continuous monitoring (LTCM) monitor used in the interventional (screening) arm of the study.

SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQIRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the commercial launch of its Zio® monitor and Zio® long-term continuous (LTCM) ambulatory ECG monitoring service in Austria, the Netherlands, Spain, and Switzerland. The Zio monitor and ZEUS (Zio ECG Utilization Software) system received the European Union’s CE Marking Under Medical Device Regulation (EU MDR) in December 2023. The Zio LTCM service provides up to 14 days of continuous, uninterrupted ECG monitoring, marking a significant advancement in these countries, compared to older, commonly used 24- to 48-hour Holter monitoring services1.

SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQIRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will present at the following investor conferences in September:

SAN FRANCISCO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQIRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that Brice Bobzien, Chief Financial Officer, will step down for personal reasons effective August 31, 2024. He will be succeeded by Daniel Wilson, iRhythm’s current Executive Vice President of Corporate Development and Investor Relations. Mr. Bobzien has served as the CFO since 2022, and he will continue to serve the Company in an advisory capacity into 2025 following the succession to ensure a smooth transition.

SAN FRANCISCO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQIRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2024.

SAN FRANCISCO, July 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQIRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2024 after the close of trading on Thursday, August 1, 2024. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

SAN FRANCISCO, June 17, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQIRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company has successfully launched the initial phases of its previously disclosed manufacturing automation plans, marking a significant corporate milestone expected to set the stage for future growth and innovation while also yielding substantial cost savings.

SAN FRANCISCO, June 04, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQIRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Truist Securities MedTech Conference.